Sites selling fake weight-loss drugs getting the chop
Cybersecurity firm BrandShield has taken down more than 250 websites selling fake versions of popular weight-loss and diabetes drugs in the GLP-1 class, says CEO Yoav Keren.
BrandShield, which shared this information exclusively with Reuters, said that out of the 279 pharmacy websites the company closed in 2023 for selling drugs intended to treat metabolic conditions, more than 90% were related to GLP-1 medicines.
Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound are GLP-1 drugs. They were developed for type 2 diabetes but also reduce food cravings and cause the stomach to empty more slowly. The drugs have been shown to help patients lose on average as much as 20% of their weight, fuelling explosive demand and a burgeoning global market for fake versions.
Cases of harm linked to fake versions of Ozempic and other GLP-1s have been reported in at least nine countries, including Belgium, Britain, Switzerland and the US.
“I wouldn ’ t be surprised to see criminals try to use the growing popularity of these drugs to sell more counterfeits,” said Keren.
Websites taken down for selling bogus GLP-1s represented just over 15% of the 1,655 websites BrandShield reported in 2023 for peddling counterfeit hormone-related drugs, central nervous system medicines and cancer treatments.
Websites selling counterfeit GLP-1s were less common in 2022 when the company identified 34 such sites to be closed. However, it was not targeting all of the GLP-1 drugs that year — as it did in 2023, said Keren.
He said that last year his firm did not find the same concentration of a particular class of drug in any treatment category as it did for GLP-1s as metabolic treatments.
BrandShield worked with the Pharmaceutical Security Institute (PSI), an industry-backed organisation, to take down these websites. PSI’s members, which include Lilly and Novo, chose which drugs to target, according to Keren.
The CEO said his company got these websites taken down by collecting evidence that their products were counterfeit and submitting that to the service providers hosting the site.
When permitted or requested by its drugmaker customers, BrandShield will share that intelligence with law enforcement agencies. The US Food and Drug Administration said in December it was investigating counterfeit Ozempic in the legitimate US supply chain.
BrandShield took down 3,968 listings on social media platforms for fake drugs in all categories last year, almost 60% of which were found on Facebook, according to a new report from the company.
It removed more than 6,900 illegal drug listings across social media platforms and marketplaces in total, including 992 marketplaces in India, 544 in Indonesia, 364 in China and 114 in Brazil. Keren said the company did not have data on how many of these social media listings and marketplaces were selling fake versions of GLP-1s.
I WOULDN’T BE SURPRISED TO SEE CRIMINALS TRY TO USE THE GROWING POPULARITY OF THESE DRUGS TO SELL MORE COUNTERFEITS